<img src="https://ml.globenewswire.com/Resource/Download/0db01792-5780-4377-a289-8872f29ba02f?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Asimov Company Logo.png" alt="Asimov"/>As part of a multi-product collaboration, Asimov’s CHO Edge system enabled a high performance cell line for a first-in-class bispecific antibody, achieving clonal titers of over 10 g/L in a platform fed-batch processBOSTON, Sept. 14, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a cell line development partnership with Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment of cancer. As part of a broader collaboration across multiple products, Asimov successfully delivered a cell line for Sidewinder’s bispecific antibody candidate for solid tumors. “We are excited to be partnering with Sidewinder Therapeutics to advance their novel bispecific, which represents a powerful approach to targeting and treating solid tumors,” said Alec Nielsen, co-founder and CEO at Asimov. “Complex molecules such as Sidewinder’s 4-chain bispecific can be challenging to express, and achieving such high titers for this molecule is a testament to the strength of both our team and our CHO Edge System.” Asimov has worked closely with the Sidewinder team on a custom cell line development program for this 4-chain bispecific antibody. In order to achieve the required expression levels and quality attributes, Sidewinder relied on Asimov’s CHO Edge system, which combines a GS knock-out CHO host, hyperactive transposase, genetic parts library, and Kernel, Asimov's AI-driven genetic design software. “With a pipeline of first-in-class bispecific ADCs, we needed to find a cell line development partner with the technical capabilities required to deliver high expression levels while simultaneously achieving consistent product quality,” said Eric Murphy, Ph.D., co-founder and CEO at Sidewinder. “The team at Asimov has exceeded expectations, and we’re excited to be progressing toward the clinic with such a high performing cell line.” About Asimov Asimov’s mission is to advance humanity’s ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform – from cells to software – to design and manufacture next-generation therapeutics, including biologics, cell/gene therapies, and RNA through a combination of products, services, and collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management &amp; Research Company. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=Y1eObtJZFOUnfmllj83JP0IwxRhCyyrTku-3nTNHWvxvu-XBDMZ6GnWl0KJ4k8L5xgXOzzYMuyHpvYrFGNMp4w==" rel="nofollow" target="_blank" title="">www.asimov.com</a>. About Sidewinder Therapeutics Sidewinder Therapeutics is developing next-generation bispecific ADCs designed to expand the therapeutic window through enhanced tumor specificity and internalization. Founded in 2023, Sidewinder is headquartered in San Diego and has raised a total of $162 million from a world-class investor syndicate. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=AphZ5PADv8O-zjF8ifVatFQTC-JWuQagZoEcyHaciFSjZ3UARRYZkJcQ2zqauElXv1YO8dFXZfl5xtjRkHUQRvkCCR3YYvnLpA64Dqy3MEQ=" rel="nofollow" target="_blank" title="">www.sidewinderbio.com</a>. Contact media@asimov.com <img alt="" src='https://ml.globenewswire.com/media/OGE1Y2UyMTEtOWU5My00YmZhLWE0OTQtMjA1NjNjZWVkYmEyLTEzMTY2MDktMjAyNi0wOS0xNC1lbg==/tiny/Asimov.png' referrerpolicy='no-referrer-when-downgrade' />

Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn